NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $2.30 +0.09 (+4.07%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nuvation Bio Stock (NYSE:NUVB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvation Bio alerts:Sign Up Key Stats Today's Range$2.22▼$2.3250-Day Range$2.00▼$3.2752-Week Range$1.17▼$4.16Volume2.16 million shsAverage Volume1.53 million shsMarket Capitalization$573.25 millionP/E RatioN/ADividend YieldN/APrice Target$6.40Consensus RatingBuy Company OverviewNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More… Nvidia warning urgent (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Nuvation Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreNUVB MarketRank™: Nuvation Bio scored higher than 76% of companies evaluated by MarketBeat, and ranked 266th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has only been the subject of 3 research reports in the past 90 days.Read more about Nuvation Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.29) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuvation Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.39% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Nuvation Bio has recently decreased by 53.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.39% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Nuvation Bio has recently decreased by 53.45%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.77 News SentimentNuvation Bio has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nuvation Bio this week, compared to 2 articles on an average week.Search Interest6 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows6 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of Nuvation Bio is held by insiders.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVB Stock News HeadlinesInsider Buying: Nuvation Bio Inc. (NYSE:NUVB) Director Purchases 100,000 Shares of StockOctober 11, 2024 | insidertrades.comNuvation Bio (NYSE:NUVB) Shares Down 4.3% - What's Next?October 27, 2024 | americanbankingnews.comNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. November 2, 2024 | Porter & Company (Ad)Wedbush Issues Optimistic Forecast for Nuvation Bio EarningsOctober 25, 2024 | americanbankingnews.comFY2028 Earnings Estimate for Nuvation Bio Issued By WedbushOctober 24, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Stock Rating Reaffirmed by WedbushOctober 23, 2024 | americanbankingnews.comNuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish MarketOctober 21, 2024 | seekingalpha.comIs Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds?October 16, 2024 | msn.comSee More Headlines NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $1.51 at the start of the year. Since then, NUVB shares have increased by 52.3% and is now trading at $2.30. View the best growth stocks for 2024 here. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.09. The firm earned $1.44 million during the quarter. Who are Nuvation Bio's major shareholders? Nuvation Bio's top institutional shareholders include Assenagon Asset Management S.A. (0.18%), SG Americas Securities LLC (0.03%), Marquette Asset Management LLC (0.02%) and Exchange Traded Concepts LLC (0.02%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman, Xiangmin Cui and Robert Mashal. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nuvation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/05/2024Today11/02/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.40 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+178.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax Margin-35,590.24% Return on Equity-16.57% Return on Assets-13.93% Debt Debt-to-Equity RatioN/A Current Ratio11.49 Quick Ratio11.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.83Miscellaneous Outstanding Shares249,240,000Free Float236,608,000Market Cap$573.25 million OptionableOptionable Beta1.36 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:NUVB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.